Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,411Revenue (TTM) $M37.2Net Margin (%)-784.0Altman Z-Score9.8
Enterprise Value $M4,217EPS (TTM) $-7.1Operating Margin %-742.0Piotroski F-Score5
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-784.0Higher ROA y-yY
Price/Book23.310-y EBITDA Growth Rate %--Quick Ratio5.5Cash flow > EarningsY
Price/Sales1065-y EBITDA Growth Rate %--Current Ratio5.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-89.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-188.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M51.4ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with TSRO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
TSRORon Baron 2016-06-30 Add$37.21 - $84.05
($44.58)
$ 85.8893%Add 85.00%3,700
TSRORon Baron 2016-03-31 Buy $32.01 - $52.32
($40.2)
$ 85.88114%New holding2,000
TSRODavid Swensen 2015-12-31 Sold Out -0.08%$40.35 - $52.91
($47.98)
$ 85.8879%Sold Out0
TSRODavid Swensen 2015-09-30 Buy 0.08%$38.97 - $65.8
($54.68)
$ 85.8857%New holding6,238
TSROLeon Cooperman 2015-06-30 Sold Out -0.05%$50.84 - $64.65
($57.38)
$ 85.8850%Sold Out0
TSROLeon Cooperman 2015-03-31 Buy 0.05%$36.62 - $61.41
($47.12)
$ 85.8882%New holding50,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TSRO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


TSRO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Hanke Jeffrey H.Executive VP, R&D and CSO 2016-06-30Sell12,500$74.3515.51view
English Edward CVP of Finance & Administration 2016-06-10Sell7,000$40.75110.75view
Weller Harry R10% Owner 2016-03-18Buy1,420,858$35.19144.05view
Viswanathan Ravi10% Owner 2016-03-18Buy1,420,858$35.19144.05view
SANDELL SCOTT D10% Owner 2016-03-18Buy1,420,858$35.19144.05view
MOTT DAVID MDirector, 10% Owner 2016-03-18Buy1,420,858$35.19144.05view
KERINS PATRICK J10% Owner 2016-03-18Buy710,429$35.19144.05view
BASKETT FOREST10% Owner 2016-03-18Buy1,420,858$35.19144.05view
BARRIS PETER J10% Owner 2016-03-18Buy1,420,858$35.19144.05view
BARRETT M JAMES10% Owner 2016-03-18Buy710,429$35.19144.05view

Quarterly/Annual Reports about TSRO:

News about TSRO:

Articles On GuruFocus.com
Major Second Quarter Purchases for Cohen include Tesaro, Pernix Jul 20 2016 
Steven Cohen Hits Another Home Run in Oncology Jul 07 2016 
David Swensen Bets on Antero Resources Mar 10 2016 
David Swensen's Transactions Show Diversity of Portfolio Nov 19 2015 

More From Other Websites
TESARO Announces Participation at Four Investor Conferences Aug 24 2016
TESARO Announces Participation at Four Investor Conferences Aug 24 2016
Medivation Scores Premium in Sale to Pfizer Aug 22 2016
Nice Recovery, But Momentum Is Missing Aug 17 2016
Coverage initiated on Tesaro by RBC Capital Mkts Aug 12 2016
TESARO, INC. Financials Aug 11 2016
It May Be Dull, but That's No Reason to Be Negative Aug 09 2016
Edited Transcript of TSRO earnings conference call or presentation 4-Aug-16 8:15pm GMT Aug 05 2016
TESARO, INC. Files SEC form 10-Q, Quarterly Report Aug 05 2016
Tesaro reports 2Q loss Aug 04 2016
Tesaro reports 2Q loss Aug 04 2016
Read this press release » Aug 04 2016
Tesaro Announces Second-Quarter 2016 Operating Results Aug 04 2016
Tesaro Announces Second-Quarter 2016 Operating Results Aug 04 2016
TESARO, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 04 2016
Q2 2016 TESARO Inc Earnings Release - After Market Close Aug 04 2016
Gilead Has a Problem. These Three Biotechs Could Be the Solution Jul 22 2016
TESARO to Announce Second-Quarter 2016 Financial Results on August 4, 2016 Jul 21 2016
10 Stocks That Could Ruin Your Retirement Jul 15 2016
ENGOT and TESARO Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial Jul 08 2016
ENGOT and TESARO Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial Jul 08 2016
TESARO, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Jul 07 2016
TESARO Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters Jul 07 2016
TESARO Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters Jul 07 2016
Steven Cohen Hits Another Home Run in Oncology Jul 07 2016
Buyout target Medivation says cancer drug could be 'best in class' Jul 06 2016
TESARO Announces Pricing of Public Offering of Common Stock Jun 30 2016
TESARO Announces Proposed Public Offering of Common Stock Jun 30 2016
TESARO's Niraparib Significantly Improved Progression-Free Survival for Patients With Ovarian Cancer... Jun 29 2016
TESARO Announces Rolapitant Data Presentations at the 2016 MASCC/ISOO Annual Meeting on Supportive... Jun 23 2016
TESARO Provides Pipeline Update at ASCO Investor Briefing Jun 04 2016
TESARO Congratulates Dr. Mary Lynne Hedley on Being Named Life Science "Entrepreneur of the Year" by... May 19 2016
TESARO Announces Five Abstracts to be Presented at the 2016 American Society of Clinical Oncology... May 18 2016
Tesaro reports 1Q loss May 05 2016
TESARO Announces First-Quarter 2016 Operating Results May 05 2016
Read this press release » May 05 2016
TESARO Celebrates Oncology Nurses With Premiere of "Heroic Hearts" Documentary at Oncology Nursing... Apr 27 2016
TESARO Announces Submission of Investigational New Drug Application for Anti-TIM-3 Antibody TSR-022... Apr 25 2016
TESARO to Announce First Quarter 2016 Financial Results on May 5, 2016 Apr 21 2016
TESARO Announces Global Prostate Cancer Collaboration and Licensing Agreement With Janssen Apr 06 2016
TESARO Announces Appointment of Dr. Kavita Patel to Board of Directors Apr 04 2016
TESARO Announces Enrollment of First Patient in Phase 1 Clinical Trial of TSR-042 Mar 29 2016
Tesaro reports 4Q loss Feb 25 2016
Tesaro reports 3Q loss Oct 29 2015
Tesaro reports 2Q loss Aug 06 2015
Tesaro reports 1Q loss Apr 30 2015
Tesaro beats 3Q profit forecasts Nov 06 2014

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)